Bob Evans Farms, Inc. (NASDAQ:BOBE) confirmed receipt of notice of nominations from Sandell Asset Management (“Sandell”) for candidates to stand for election to the Company’s Board of Directors. The Company’s Board of Directors will carefully consider and evaluate Sandell’s notice and nominations and will communicate with the Company’s shareholders in due course. Bob Evans Farms Inc (NASDAQ:BOBE) shares after opening at $45.19 moved to $48.68 on last trade day and at the end of the day closed at $47.29 . Company price to sales ratio in past twelve months was calculated as 0.86 and price to cash ratio as 216.22. Bob Evans Farms Inc (NASDAQ:BOBE) showed a positive weekly performance of 8.46%.
Depomed, Inc. (NASDAQ:DEPO) announced it has entered into settlement agreements with two of the three defendants involved in Depomed’s ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed’s Gralise®(gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the other Gralise ANDA filer. Depomed Inc (NASDAQ:DEPO) shares advanced 8.10% in last trading session and ended the day on $14.28. DEPO return on equity ratio is recorded as 44.10% and its return on assets is 18.50%. Depomed Inc (NASDAQ:DEPO) yearly performance is 162.98%.
Elizabeth Arden Inc. (NASDAQ:RDEN) jumped 10% Thursday on reports the cosmetics maker hired Goldman Sachs to discuss a potential sale. The news was reported by Reuters , which cited anonymous people familiar with the matter. Elizabeth Arden, Inc. (NASDAQ:RDEN) shares moved up 13.10% in last trading session and was closed at $ 36.00 while trading in range of $31.40 – $36.25 – Elizabeth Arden, Inc. (NASDAQ:RDEN) year to date (YTD) performance is 1.55%.
Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call. Array Biopharma Inc (NASDAQ:ARRY) weekly performance is 6.51%. On last trading day company shares ended up $4.09. Array Biopharma Inc (NASDAQ:ARRY) distance from 50-day simple moving average (SMA50) is -13.08%. Analysts mean target price for the company is $7.50.